About

Our Mission

To prepare for the widespread adoption of blood-based biomarkers in clinical practice to enable a more simple, timely, and accurate diagnostic experience for patients.

Our Background

In January 2023, the Global CEO Initiative on Alzheimer’s Disease (CEOi) convened a diverse group of stakeholders to join a BBM Workgroup with the goal of preparing relevant stakeholders (e.g. practicing clinicians and health systems) for widespread adoption of BBMs to enable a more simple, timely, and accurate Alzheimer’s diagnostic experience, starting with the US​. 

Over 90 Participants

The BBM Workgroup attracted more than 90 participants, including experts from healthcare, academia, non-profit, government, venture capital, industry, and patient advocacy.

The first phase of the BBM Workgroup consisted of three Workstreams:

BBM Workgroup Members

  • Sasha Bozeat

    Steering Committee
    Roche

  • John Dwyer

    Steering Committee
    Global Alzheimer's Platform Foundation

  • Drew Holzapfel

    Steering Committee Global CEO Initiative on Alzheimer’s Disease

  • Daryl Jones

    Steering Committee Eisai

  • Jim Murray

    Steering Committee Davos Alzheimer’s Collaborative

  • Katie Partrick

    Steering Committee Global CEO Initiative on Alzheimer’s Disease

  • Emily Scholler

    Steering Committee Global CEO Initiative on Alzheimer’s Disease

  • Ben Tiede

    Steering Committee Global CEO Initiative on Alzheimer’s Disease

  • Suzanne Schindler

    Lead / Workstream A
    Washington University School of Medicine

  • Oskar Hansson

    Lead / Workstream A
    Lund University

  • Douglas Galasko

    Core Team / Workstream A
    University of California, San Diego

  • Ana Pereira

    Core Team / Workstream A Icahn School of Medicine, Mount Sinai

  • Stephen Salloway

    Core Team / Workstream A Alpert Medical School, Brown University

  • Marc Suarez-Calvet

    Core Team / Workstream A BarcelonaBeta Brain Research Center

  • Gil Rabinovici

    Core Team / Workstream A University of California, San Francisco

  • Michelle Mielke

    Lead / Workstream B
    Wake Forest University School of Medicine

  • Chi Udeh-Momoh

    Lead / Workstream B
    Wake Forest University School of Medicine

  • Matthew Anderson

    Core Team / Workstream B
    Atrium Health

  • John Wesson Ashford

    Core Team / Workstream B Stanford University School of Medicine

  • Andreas Jeromin

    Core Team / Workstream B AlzPath

  • Pei Jung Lin

    Core Team / Workstream B Tufts University, School of Medicine

  • Allyson Rosen

    Core Team / Workstream B Stanford University School of Medicine

  • Jamie Tyrone

    Core Team / Workstream B Patient Advocate

  • Lawrence Vandevrede

    Core Team / Workstream B University of California, San Francisco

  • Deanna Willis

    Core Team / Workstream B Indiana University School of Medicine

  • Ara Khachaturian

    Lead / Workstream C
    Campaign to Prevent Alzheimer's Disease

  • Joan Weiss

    Lead / Workstream C
    Health Resources & Services Administration, U.S. Department of Health & Human Services

  • Malaz Boustani

    Core Team / Workstream C Indiana University School of Medicine

  • Brittany Cassin

    Core Team / Workstream C Digicare Realized

  • Elyse Perweiler

    Core Team / Workstream C
    Rowan University School of Osteopathic Medicine

 BBM Workgroup Participating Organizations

BBM Workgroup Sponsors

Sponsorship does not represent promotion or endorsement of any individual diagnostic test or platform.